Cetuximab and Other Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Non-Small Cell Lung Cancer
Cetuximab and Other Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Non-Small Cell Lung Cancer
复制标题
DOI：
10.1634/theoncologist.2008-0153
复制
发表时间：
2009-01-01
期刊：
影响因子：
5.8
通讯作者：
Rossi, Antonio
中科院分区：
文献类型：
--
作者：
Gridelli, Cesare;Maione, Paolo;Rossi, Antonio
非小细胞肺癌（NSCLC）占所有新诊断肺癌的约85%。不幸的是，很少有NSCLC患者适合根治性治疗。由于大多数NSCLC患者在诊断时患有晚期疾病，因此化疗代表了标准治疗，尽管迄今为止，这种方法已经达到了平台期。随着对肿瘤生物学和肿瘤发生机制认识的提高，表皮生长因子受体（EGFR）（ErbB家族成员）已被确定为NSCLC治疗的分子靶点。EGFR通常在NSCLC中过表达，并与预后受损相关;因此，其抑制可能通过抑制肿瘤增殖改善临床结局。阻断EGFR的策略包括酪氨酸激酶抑制剂、单克隆抗体、配体连接毒素和反义方法。本文重点介绍了使用抗EGFR单克隆抗体（包括西妥昔单抗）治疗NSCLC，这是文献中存在的最大数据量。最近，在晚期NSCLC患者中进行的一项III期随机试验显示，西妥昔单抗联合化疗与单纯化疗相比，具有统计学显著的生存优势。其他抗EGFR单克隆抗体，如帕尼单抗、马妥珠单抗、尼妥珠单抗和ch 806，正处于治疗晚期NSCLC的不同开发阶段。肿瘤学家2009; 14：601-611
Non-small cell lung cancer (NSCLC) accounts for about 85% of all new diagnoses of lung cancer. Unfortunately, few NSCLC patients are suitable for radical treatment for curative intent. Because most patients with NSCLC have advanced disease at diagnosis, chemotherapy represents the standard of care, although, to date, a plateau has been reached with this approach. Improvements in the knowledge of tumor biology and mechanisms of oncogenesis have identified the epidermal growth factor receptor (EGFR), a member of the ErbB family, as a molecular target for NSCLC treatment. EGFR is commonly overexpressed in NSCLC and has been associated with impaired prognosis; therefore, its inhibition may lead, through the suppression of tumor proliferation, to improvement in clinical outcomes. Strategies to block EGFR include tyrosine kinase inhibitors, monoclonal antibodies, ligand-linked toxins, and antisense approaches. This article focuses on the treatment of NSCLC with the anti-EGFR monoclonal antibodies, including cetuximab, for which the largest amount of data in the literature exists. Recently, a phase III randomized trial performed in advanced NSCLC patients yielded a statistically significant survival advantage for patients treated with cetuximab plus chemotherapy versus chemotherapy alone. Other anti-EGFR monoclonal antibodies, such as panitumumab, matuzumab, nimotuzumab, and ch806, are in different stages of development for the treatment of advanced NSCLC. The Oncologist 2009; 14: 601-611